Gewinn- und Verlustrechnung von Zimmer Biomet Holdings, Inc.

ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.

Zimmer Biomet (NYSE: ZBH) reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines. U.S. organic constant-currency sales rose 4.6%, while international sales increased 3.1%. Chairman, President and

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zimmer Biomet NYSE: ZBH reported second-quarter 2026 net sales of $2.177 billion, up 4.8% on a reported basis and 4.0% on an organic constant-currency basis, as growth in hips, specialty businesses and technology helped offset weaker performance in certain other product lines.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript

ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.

While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $2.07 per share a year ago.

Second quarter net sales of $2.177 billion increased 4.8% on a reported basis, 4.7% on a constant currency1 basis and 4.0% on an organic constant currency1 basis Second quarter diluted earnings per share were $1.03, an increase of 33.8%; adjusted1 diluted earnings per share were $2.07, consistent with the prior year period Company updates full-year 2026 financial guidance WARSAW, Ind., Aug. 5, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and (SIX: ZBH) today reported financial results for the quarter ended June 30, 2026.